CIK 0001818794 · Large accelerated filer
Dyne Therapeutics, Inc.
Sign in to watch- Ticker
- DYN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364883909
- Phone
- (781) 786-8230
- Business address
- 1560 TRAPELO ROAD, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $40,000
- in 1 filing
- Open-market sales, last 90 days
- $247,777
- in 3 filings, $248K under 10b5-1 plans
Net −$207,777. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-22 | Lubner David Charles Director | Grant or award · Stock option (right to buy) | +25,133 | 25,133 | ||
| 2024-05-20 | Beskrovnaya Oxana Chief Scientific Officer | Option exercise 10b5-1 | +30,426 | $1.03 | $31K | 180,073 |
| 2024-05-20 | Beskrovnaya Oxana Chief Scientific Officer | Sale 10b5-1 | −17,134 | $32.49 | $557K | 162,939 |
| 2024-05-20 | Beskrovnaya Oxana Chief Scientific Officer | Sale 10b5-1 | −12,147 | $33.51 | $407K | 150,792 |
| 2024-05-20 | Beskrovnaya Oxana Chief Scientific Officer | Sale 10b5-1 | −1,145 | $34.08 | $39K | 149,647 |
| 2024-05-20 | Beskrovnaya Oxana Chief Scientific Officer | Option exercise · Stock option (right to buy) 10b5-1 | −30,426 | 0 | ||
| 2024-05-16 | Beskrovnaya Oxana Chief Scientific Officer | Sale 10b5-1 | −2,222 | $28.20 | $63K | 150,130 |
| 2024-05-16 | Beskrovnaya Oxana Chief Scientific Officer | Sale 10b5-1 | −483 | $28.59 | $14K | 149,647 |
| 2024-05-16 | Farwell Wildon Chief Medical Officer | Sale 10b5-1 | −1,956 | $28.20 | $55K | 148,604 |
| 2024-05-16 | Farwell Wildon Chief Medical Officer | Sale 10b5-1 | −425 | $28.59 | $12K | 148,179 |
| 2024-05-16 | HIGH SUSANNA GATTI Chief Operating Officer | Sale 10b5-1 | −2,249 | $28.20 | $63K | 154,551 |
| 2024-05-16 | HIGH SUSANNA GATTI Chief Operating Officer | Sale 10b5-1 | −489 | $28.59 | $14K | 154,062 |
| 2024-05-16 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −2,126 | $28.20 | $60K | 117,157 |
| 2024-05-16 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −462 | $28.59 | $13K | 116,695 |
| 2024-05-16 | McNeill Jonathan Chief Business Officer | Sale 10b5-1 | −2,279 | $28.20 | $64K | 137,129 |
| 2024-05-16 | McNeill Jonathan Chief Business Officer | Sale 10b5-1 | −495 | $28.59 | $14K | 136,634 |
| 2024-03-25 | Cox John See Remarks | Grant or award · Stock Option (Right to Buy) | +679,853 | 679,853 | ||
| 2024-03-12 | Farwell Wildon Chief Medical Officer | Sale 10b5-1 | −1,030 | $25.58 | $26K | 150,560 |
| 2024-03-11 | HIGH SUSANNA GATTI Chief Operating Officer | Sale 10b5-1 | −2,292 | $25.70 | $59K | 156,800 |
| 2024-03-11 | McNeill Jonathan Chief Business Officer | Option exercise 10b5-1 | +17,825 | $5.54 | $99K | 159,009 |
Page 19 of 29 · 561 trades